In a report released yesterday, Daina Graybosch from SVB Securities maintained a Buy rating on iTeos Therapeutics (ITOS – Research Report). The company’s shares opened today at $14.75.
Graybosch covers the Healthcare sector, focusing on stocks such as BioNTech SE, Merck & Company, and Nektar Therapeutics. According to TipRanks, Graybosch has an average return of -18.5% and a 30.33% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for iTeos Therapeutics with a $39.67 average price target, representing a 168.95% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $54.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $28.05 and a one-year low of $12.52. Currently, iTeos Therapeutics has an average volume of 244.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Read More on ITOS:
- iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
- Down More Than 50%: 2 ‘Strong Buy’ Stocks That Are Too Cheap to Ignore
- iTeos Therapeutics price target lowered to $33 from $45 at Wedbush
- iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- iTeos Therapeutics expects cash to provide runway into 2026
